SEC For	rm 4 FORM	4	UNITED	STAT	ſES	SEC	CUR	ITIE	ES AND	EX	СНА	NGE (сом	MIS	SION				
			Washington, D.C. 20549												OMB APPROVAL				
Section 16. Form 4 or Form 5 obligations may continue. See					AT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										HIP	Estim	OMB Number: 3235-0 Estimated average burden hours per response:		3235-0287 n 0.5
1. Name and Address of Reporting Person* Hineline Lawrence J.					2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITCI]									Cheo	lationship c ck all applic Directo	able)	g Pers	uer vner specify	
(Last) (First) (Middle) C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET					3. Date of Earliest Transaction (Month/Day/Year) 03/06/2023									Х	below)		e dife (spec below) e of Finance CFO		
(Street) NEW YORK NY 10016					4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person										n				
(City) (State) (Zip)																			
		Tah		Doriva		Soci	ritios		auirod D	iend	osod o	f or Br	nofic	ally		1			
				2. Transac Date (Month/Da	ction	2A. Exe	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (Disposed Of (D) (Instr. 3		red (A) o	r	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code V	, ,	Amount (A) or (D)		Prio	Turin		tion(s)			(11501.4)
		1	· · ·	ə.g., pu	its, c	alls,	warra	ants	, options	, co	nvertil	ble sec	urities	s)					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	ansacti ode (Ins	ion c str. [4 [c	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	ode V	, ((A)	(D)	Date Exercisable		piration te	Title	Amou or Numb of Share	er					
Restricted Stock Units	(1)	03/06/2023			A	3	39,398		(2)		(2)	Common Stock	39,3	98	\$0.00	39,39	8	D	

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. On March 6, 2023, the reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

/s/ Lawrence J. Hineline
** Signature of Reporting Person

03/08/2023 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.